Capacity expansion GRAM is investing heavily in new sterile fill-finish capacity and GMP facilities, signaling readiness to take on larger late-stage and commercial programs and reduce supply gaps for clients.

Device collaboration With an ongoing partnership with SHL Medical and a focus on autoinjectors and on body devices, GRAM is well positioned to support manufacturers seeking integrated drug delivery solutions and device-ready manufacturing.

Strategic leadership A stable leadership team under a growth focused, investor backed plan indicates GRAM's commitment to expanding CDMO services; ideal for long term partnerships and multi program supply arrangements.

US manufacturing Based in Michigan with a scalable platform and GMP compliant facilities, GRAM offers US based sterile manufacturing to support near term supply chain resilience and regulatory alignment for domestic pharma clients.

Talent and quality Award winning workplace culture and recognized growth trajectory suggest a capable, engaged workforce and strong operational execution, reducing project risk and enabling timely delivery for complex sterile programs.